Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.
The ImplementatioN of perSonalized medicine In NSCLC in Central Europe: EGFR testing, Histopathology, and clinical feaTures (INSIGHT) observational study assessed both implementation of epidermal growth factor receptor (EGFR) mutation testing and treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) in a real-world setting in Central Europe. A total of 1785 patients from 14 cancer centers of six Central European countries were enrolled. EGFR mutations were detected in tumors of 13.8% of the patients. More than 70% of patients with advanced EGFR mutation-positive NSCLC received EGFR tyrosine kinase inhibitors as first-line therapy. The INSIGHT study demonstrated the establishment of EGFR mutation testing, a mutation rate consistent with other Caucasian patients populations, and adherence to current guidelines regarding treatment of patients with EGFR mutation-positive tumors in Central Europe.
Department of Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Rodryg
R
Ramlau
University Clinic, Golnik, Slovenia.
Tanja
T
Cufer
Specialized Hospital of St Zoerardus Zobor, Nitra, Slovakia.
Peter
P
Berzinec
Medical University of Gdansk, Gdansk.
Rafal
R
Dziadziuszko
The Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland.
Włodzimierz
W
Olszewski
Medical University of Graz, Graz.
Helmut
H
Popper
Boehringer Ingelheim RCV Vienna.
Paolo
P
Bajcic
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Ladislav
L
Dusšk
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Zuzana
Z
Zbozinkova
Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: robert.pirker@meduniwien.ac.at.
Robert
R
Pirker
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism*; D005060:Europe; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D055815:Young Adult
C512478:EGFR protein, human; D066246:ErbB Receptors